- Home
- LQDA vs ECAT Comparison
LQDA vs ECAT Comparison
Compare LQDA & ECAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LQDA
- ECAT
- Stock Information
- Founded
- LQDA 2004
- ECAT 2021
- Country
- LQDA United States
- ECAT United States
- Employees
- LQDA N/A
- ECAT N/A
- Industry
- LQDA Biotechnology: Pharmaceutical Preparations
- ECAT Trusts Except Educational Religious and Charitable
- Sector
- LQDA Health Care
- ECAT Finance
- Exchange
- LQDA Nasdaq
- ECAT Nasdaq
- Market Cap
- LQDA 1.9B
- ECAT 1.6B
- IPO Year
- LQDA 2018
- ECAT N/A
- Fundamental
- Price
- LQDA $24.08
- ECAT $16.64
- Analyst Decision
- LQDA Strong Buy
- ECAT
- Analyst Count
- LQDA 9
- ECAT 0
- Target Price
- LQDA $32.67
- ECAT N/A
- AVG Volume (30 Days)
- LQDA 2.9M
- ECAT 278.6K
- Earning Date
- LQDA 11-12-2025
- ECAT 01-01-0001
- Dividend Yield
- LQDA N/A
- ECAT 9.20%
- EPS Growth
- LQDA N/A
- ECAT N/A
- EPS
- LQDA N/A
- ECAT 2.39
- Revenue
- LQDA $19,322,000.00
- ECAT N/A
- Revenue This Year
- LQDA $405.58
- ECAT N/A
- Revenue Next Year
- LQDA $373.93
- ECAT N/A
- P/E Ratio
- LQDA N/A
- ECAT $7.15
- Revenue Growth
- LQDA 30.20
- ECAT N/A
- 52 Week Low
- LQDA $9.71
- ECAT $14.02
- 52 Week High
- LQDA $29.94
- ECAT $17.30
- Technical
- Relative Strength Index (RSI)
- LQDA 52.50
- ECAT 58.08
- Support Level
- LQDA $21.35
- ECAT $16.52
- Resistance Level
- LQDA $23.33
- ECAT $16.73
- Average True Range (ATR)
- LQDA 1.18
- ECAT 0.15
- MACD
- LQDA 0.05
- ECAT 0.03
- Stochastic Oscillator
- LQDA 83.30
- ECAT 86.12
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
About ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.